Arcus Biosciences Net Income Over Time
| RCUS Stock | USD 19.96 1.40 6.55% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Arcus Biosciences Performance and Arcus Biosciences Correlation. Is there potential for Biotechnology market expansion? Will Arcus introduce new products? Factors like these will boost the valuation of Arcus Biosciences. Anticipated expansion of Arcus directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Arcus Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.20) | Revenue Per Share | Quarterly Revenue Growth (0.46) | Return On Assets | Return On Equity |
Arcus Biosciences's market price often diverges from its book value, the accounting figure shown on Arcus's balance sheet. Smart investors calculate Arcus Biosciences' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Arcus Biosciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Arcus Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Arcus Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Arcus Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Arcus Biosciences and related stocks such as Immunitybio, Denali Therapeutics, and Galapagos NV ADR Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IBRX | (2 M) | (2 M) | (2 M) | (2 M) | (6.2 M) | (236.9 M) | (120.8 M) | (96.4 M) | (96.2 M) | (65.8 M) | (221.9 M) | (346.8 M) | (416.6 M) | (583.2 M) | (413.6 M) | (372.2 M) | (353.6 M) |
| DNLI | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (16.8 M) | (86.7 M) | (88.2 M) | (36.2 M) | (197.6 M) | 71.1 M | (290.6 M) | (326 M) | (145.2 M) | (422.8 M) | (380.5 M) | (361.5 M) |
| GLPG | (3.6 M) | (33.1 M) | (5.7 M) | (8.1 M) | 33.2 M | (118.4 M) | 54 M | (115.7 M) | (29.3 M) | 149.8 M | (305.4 M) | (125.4 M) | (218 M) | 211.7 M | 74.1 M | 66.7 M | 70 M |
| COGT | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (18.1 M) | (25.5 M) | (34.5 M) | (30.3 M) | (74.8 M) | (72.3 M) | (132.6 M) | (192.4 M) | (255.9 M) | (230.3 M) | (218.8 M) |
| AGIO | (23.7 M) | (23.7 M) | (20.1 M) | (39.4 M) | (53.5 M) | (117.7 M) | (198.5 M) | (314.7 M) | (346 M) | (411.5 M) | (327.4 M) | 1.6 B | (231.8 M) | (352.1 M) | 673.7 M | 774.8 M | 813.5 M |
| VRDN | (7.2 M) | (7.2 M) | (7.2 M) | (2.2 M) | (7.9 M) | (11.3 M) | (12.7 M) | (26.5 M) | (32.7 M) | (41.9 M) | (110.7 M) | (79.4 M) | (129.9 M) | (237.7 M) | (269.9 M) | (243 M) | (230.8 M) |
| BEAM | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (8.7 M) | (115.3 M) | (78.3 M) | (194.6 M) | (370.6 M) | (289.1 M) | (132.5 M) | (376.7 M) | (339.1 M) | (322.1 M) |
| OCUL | (14.1 M) | (14.1 M) | (14.1 M) | (13.3 M) | (28.6 M) | (39.7 M) | (44.7 M) | (63.4 M) | (57.7 M) | (86.4 M) | (155.6 M) | (6.6 M) | (71 M) | (80.7 M) | (193.5 M) | (265.9 M) | (252.6 M) |
| LQDA | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (29.2 M) | (53.1 M) | (47.6 M) | (59.8 M) | (34.6 M) | (41 M) | (78.5 M) | (130.4 M) | (117.4 M) | (111.5 M) |
Arcus Biosciences and related stocks such as Immunitybio, Denali Therapeutics, and Galapagos NV ADR Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Arcus Biosciences financial statement analysis. It represents the amount of money remaining after all of Arcus Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Arcus Biosciences | RCUS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 3928 Point Eden |
| Exchange | New York Stock Exchange |
USD 19.96
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.